The administrative Core is essential for providing overall guidance and oversight to the Wellstone Center. The Core will be directed by Jeffrey S. Chamberlain, Ph.D. with assistance from Stephen Tapscott, M.D./Ph.D. Day to day operation ofthe Core will be handled by Ms. Roberta Miller, who has extensive experience in overseeing Center and Program Project grants.
The specific aims of the Administrative Core are as follows: 1. To integrate and manage the activities and interactions of the Projects and Cores through regular meetings, correspondence and by developing and maintaining a center website. 2. To review and report utilization of funds of all projects, cores, and resources, and to contribute to the coordination of effort to refine and standardize operational procedures within the center. 3. To provide oversight support and advice for the Director and Co-director by monitoring and reporting the activities of the center and to aid in the creation, approval, and support of a Center Advisory Committee (CAC) and local executive committee. 4. To support interaction and collaboration with the scientific and lay communities to develop relevant goals for the MDCRC within the center, as well as the NIH Science office to develop mutual MDCRC goals for research activity between Centers. The Core will also encourage collaboration and interests of scientists inside and outside the institutional community. 5. To promote and oversee the use of the core facilities, exchange of information and training and techniques among researchers within the UW and other institutions as well as patients using multiple mechanisms such as brochures, websites, and seminars.
The Administrative Core is important for providing oversight of the Center; projects and Cores. It will be supported by the P.I.; the Center co-director; an executive Committee of senior scientists affiliated with the project; and an external Center Advisory Committee.
|Lawlor, Michael W; Beggs, Alan H; Buj-Bello, Ana et al. (2016) Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons. J Neuropathol Exp Neurol 75:102-10|
|Bengtsson, Niclas E; Seto, Jane T; Hall, John K et al. (2016) Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet 25:R9-17|
|Kolwicz Jr, Stephen C; Odom, Guy L; Nowakowski, Sarah G et al. (2016) AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther 24:240-50|
|Su, Wei; Kang, John; Sopher, Bryce et al. (2016) Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem 136 Suppl 1:49-62|
|Macadangdang, Jesse; Guan, Xuan; Smith, Alec S T et al. (2015) Nanopatterned Human iPSC-based Model of a Dystrophin-Null Cardiomyopathic Phenotype. Cell Mol Bioeng 8:320-332|
|Ramos, Julian; Chamberlain, Jeffrey S (2015) Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3:1255-1266|
|Bisset, Darren R; Stepniak-Konieczna, Ewa A; Zavaljevski, Maja et al. (2015) Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet 24:4971-83|
|Guan, Xuan; Wang, Zejing; Czerniecki, Stefan et al. (2015) Use of Adeno-Associated Virus to Enrich Cardiomyocytes Derived from Human Stem Cells. Hum Gene Ther Clin Dev 26:194-201|
|Hollinger, Katrin; Chamberlain, Jeffrey S (2015) Viral vector-mediated gene therapies. Curr Opin Neurol 28:522-7|
|Cheever, Thomas R; Berkley, Dale; Braun, Serge et al. (2015) Perspectives on best practices for gene therapy programs. Hum Gene Ther 26:127-33|
Showing the most recent 10 out of 11 publications